TMCI - NASDAQ
Treace Medical Concepts, Inc.
$3.40
-5.6%Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
At a Glance
Live SnapshotTreace Medical Concepts, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Treace Medical Concepts, Inc. Cash Flow Statement
TMCI • NASDAQ
| Treace Medical Concepts, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-59M | -55.7M | -49.5M | -42.8M | -20.6M | -3.7M | -4.3M | |
10.5M | 8.4M | 5.4M | 2.1M | 685K | 1.2M | 793K | |
0.0 | 0.0 | 0.0 | 0.0 | 419K | 2.1M | 145K | |
33.8M | 30.6M | 17.4M | 8.1M | 3.4M | 919K | 815K | |
7.3M | 5M | 2M | 7.7M | 176K | 221K | 147K | |
-8.6M | -25.4M | -9.7M | -5.8M | -1.3M | -5.3M | -5.3M | |
-16M | -37.2M | -34.6M | -30.6M | -17.2M | -4.5M | -7.7M | |
INVESTING ACTIVITIES | |||||||
-13.5M | -11.6M | -11.5M | -14.8M | -2.7M | -1.1M | -1.2M | |
(0.0) | (0.0) | -20M | (61.7M) | (0.0) | (0.0) | (0.0) | |
-40.6M | -71.6M | -169.9M | -63.4M | (0.0) | (0.0) | (0.0) | |
67.3M | 118.5M | 120M | 1.7M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -61.7M | 0.0 | 0.0 | 0.0 | |
(13.3M) | (35.4M) | -81.3M | -76.5M | -2.7M | -1.1M | -1.2M | |
FINANCING ACTIVITIES | |||||||
546K | 428K | 109.4M | 2.2M | 109.4M | 364K | 0.0 | |
2.4M | 0.0 | 0.0 | 19.6M | -1.8M | 11.3M | 20M | |
-902K | -268K | -13K | -989K | 0.0 | -179K | -261K | |
2.1M | 160K | 109.4M | 20.8M | 107.7M | 11.5M | 19.7M | |
CASH FLOW SUMMARY | |||||||
-642K | -1.6M | -6.5M | -86.4M | 87.8M | 5.9M | 10.9M | |
11.4M | 13M | 19.5M | 105.8M | 18.1M | 12.1M | 1.3M | |
10.7M | 11.4M | 13M | 19.5M | 105.8M | 18.1M | 12.1M | |
-29.5M | -48.8M | -46M | -45.5M | -19.9M | -5.6M | -8.9M |
SEC Filings
TMCI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TMCI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.